Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

182

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

December 16, 2028

Study Completion Date

December 16, 2028

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

RADIATION

High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy

Twice-daily thoracic radiotherapy at a dose of 54 Gy in 30 fractions with IMRT and VMAT

DRUG

atezolizumab or durvalumab

atezolizumab 1200 mg Q3W or durvalumab 1500 mg Q4W

All Listed Sponsors

lead

Anhui Shi, MD

OTHER